Main Session
Sep
29
SS 40 - Evolving Paradigms in High-Risk Breast Cancer: Optimization and Integration of Treatment Modalities Across the Disease Continuum
322 - Phase 1b Trial of Berzosertib as a Radiosensitizer in the Post-Neoadjuvant Treatment of Chemotherapy-Resistant HER2-Negative Breast Cancer
Presenter(s)
Robert Mutter, MD - Mayo Clinic, Rochester, MN